Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Crescent Biopharma (CBIO) Interest & Investment Income (2020 - 2026)

Crescent Biopharma (CBIO) has disclosed Interest & Investment Income for 9 consecutive years, with $1.4 million as the latest value for Q1 2026.

  • For Q1 2026, Interest & Investment Income rose 669.15% year-over-year to $1.4 million; the TTM value through Mar 2026 reached $4.1 million, up 398.64%, while the annual FY2025 figure was $2.9 million, 207.4% up from the prior year.
  • Interest & Investment Income hit $1.4 million in Q1 2026 for Crescent Biopharma, up from $1.1 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $1.4 million in Q1 2026 and bottomed at $7069.0 in Q1 2022.
  • Average Interest & Investment Income over 5 years is $536736.0, with a median of $378360.0 recorded in 2024.
  • Year-over-year, Interest & Investment Income surged 9180.3% in 2022 and then plummeted 60.91% in 2024.
  • Crescent Biopharma's Interest & Investment Income stood at $378265.0 in 2022, then surged by 35.41% to $512194.0 in 2023, then crashed by 48.79% to $262288.0 in 2024, then skyrocketed by 317.48% to $1.1 million in 2025, then soared by 32.05% to $1.4 million in 2026.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at $1.4 million, $1.1 million, and $1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.